ChemoCentryx, Inc.
CCXI
CCXI was delisted on the 19th of October, 2022.
162 hedge funds and large institutions have $1.77B invested in ChemoCentryx, Inc. in 2020 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 60 increasing their positions, 39 reducing their positions, and 16 closing their positions.
225% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 16
100% more funds holding in top 10
Funds holding in top 10: 6 → 12 (+6)
91% more call options, than puts
Call options by funds: $47.2M | Put options by funds: $24.6M
54% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 39
29% more funds holding
Funds holding: 126 → 162 (+36)
13% more capital invested
Capital invested by funds: $1.57B → $1.77B (+$202M)
Top Buyers
Top Sellers
CCXI Hedge Fund Activity: Q1 2020 in Review
162 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q1 2020, worth a combined $1.77B — up 13% from $1.57B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new CCXI positions and 16 closed out — a net gain of 36 holders — while 60 added to existing stakes and 39 trimmed.
The largest buyer was Marshall Wace North America, adding an estimated $46.7M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $59.3M sold.
- 162 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q1 2020, up from 126 in Q4 2019.
- Funds reported $1.77B of ChemoCentryx, Inc. stock for Q1 2020, up 13% quarter-over-quarter.
- 52 funds opened new ChemoCentryx, Inc. positions in Q1 2020 and 16 closed out, a net change of +36 holders.
- The largest ChemoCentryx, Inc. buyer in Q1 2020 was Marshall Wace North America, an estimated $46.7M added.
- The largest ChemoCentryx, Inc. seller in Q1 2020 was Farallon Capital Management, an estimated $59.3M sold.
Based on aggregated 13F filings for Q1 2020.